Issue of Equity

RNS Number : 4423Y

e-Therapeutics plc

21 February 2013

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Issue of equity and Directors' shareholdings

21 February 2013, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that all three Non-Executive Directors of the Company have taken part of their fees for the half-year ended 31 January 2013 in ordinary shares.

The new ordinary shares were issued on 20 February 2013 at a price of 32.7 pence per share, this being the average of the closing mid-market prices for the five business days ending on the last date of the period (31 January 2013). The allotment and total holdings following this allotment are shown below.

Director	Shares allotted     20 February 2013	Ordinary shares held following allotment (% of current issued share capital)	Options over ordinary shares held (% of current issued share capital)
Oliver James	8,256	118,756 (0.09%)	143,020 (0.10%)
Rajesh Chopra	6,496	14,618 (0.01%)	0
Brad Hoy	9,357	17,857 (0.01%)	25,000 (0.02%)

Application has been made to admit the 24,109 new ordinary shares to trading on AIM and dealings in the new ordinary shares are expected to commence on 27 February 2013. Following admission the number of ordinary shares in issue in the Company will be 138,222,468. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Services Authority's Disclosure and Transparency Rules.

Contacts:

e-Therapeutics plc

Daniel Elger

Tel: [phone]

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Fred Walsh / Grishma Patel

Tel: [phone]

www.panmure.com

 

END

 

 

IOESEFFAFFDSEEE